Mutant D620N and VPS35 induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway
Yi Huang,Heng Huang,Leping Zhou,Jiawei Li,Xiang Chen,Joseph Thomas,Xiaofei He,Wenyuan Guo,Yixuan Zeng,Boon Chuan Low,Fengyin Liang,Jinsheng Zeng,Christopher A Ross,Eng-King Tan,Wanli Smith,Zhong Pei
DOI: https://doi.org/10.1093/hmg/ddac142
IF: 5.1214
2022-07-08
Human Molecular Genetics
Abstract:The D620N mutation in vacuolar protein sorting protein 35 (VPS35) gene has been identified to be linked to late onset familial Parkinson disease (PD). However, the pathophysiological roles of VPS35-D620N in PD remain unclear. Here, we generated the transgenic C. elegans overexpressing either human wild type or PD-linked mutant VPS35-D620N in neurons. C. elegans expressing VPS35-D620N, compared with non-transgenic controls, showed movement disorders and dopaminergic neuron loss. VPS35-D620N worms displayed more swimming induced paralysis but showed no defects in BSR assays, thus indicating the disruption of dopamine (DA) recycling back inside neurons. Moreover, VPS35 formed a protein interaction complex with DA transporter (DAT), RAB5, RAB11, and FAM21. In contrast, the VPS35-D620N mutant destabilized these interactions, thus disrupting DAT transport from early endosomes to recycling endosomes, and decreasing DAT at the cell suffice. These effects together increased DA in synaptic clefts, and led to dopaminergic neuron degeneration and motor dysfunction. Treatment with reserpine significantly decreased the swimming induced paralysis in VPS35-D620N worms, as compared with vehicle treated VPS35-D620N worms. Our studies not only provide novel insight into the mechanisms of VPS35-D620N-induced dopaminergic neuron degeneration and motor dysfunction via disruption of DAT function and the DA signaling pathway, but also indicate a potential strategy to treat VPS35-D620N related PD and other disorders.
genetics & heredity,biochemistry & molecular biology